Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2023-08-02 Declaration of Voting R…
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital" and explicitly references regulatory articles from the French Financial Markets Authority (AMF) regarding the disclosure of total voting rights and share capital as of a specific date (July 31, 2023). This type of periodic disclosure, detailing the total number of shares and voting rights, is a specific regulatory requirement. It does not fit the definition of an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a general Regulatory Filing (RNS). It is a specific type of regulatory update concerning share structure and voting power. While there isn't a perfect match for 'Monthly Voting Rights Disclosure', the closest category that deals with share structure and capital changes is 'Share Issue/Capital Change' (SHA) or potentially a general 'Regulatory Filing' (RNS). However, given the specific nature of reporting total voting rights under French regulation, it is a distinct regulatory disclosure. Since there is no specific code for 'Voting Rights Disclosure', and it is not a dividend announcement (DIV), director dealing (DIRS), or major shareholding change (MRQ), it falls best under the general regulatory announcement category, RNS, as it is a mandatory periodic filing that doesn't fit the other specific financial or corporate action codes. Alternatively, because it deals directly with the total number of shares and voting rights, it has elements of SHA, but SHA usually implies an *action* (issue/buyback), whereas this is a *reporting* of the current state. Given the options, RNS is the most appropriate fallback for a mandatory, non-standard regulatory report.
2023-08-02 English
Rapports financiers et d''audit semestriels/examens réduits / Rapport financier semestriel
Earnings Release Classification · 100% confidence The document is titled "MaaT Pharma fait le point sur ses activités et publie ses résultats financiers pour le deuxième trimestre 2023" (MaaT Pharma provides an update on its activities and publishes its financial results for the second quarter of 2023). It explicitly states the publication of Q2 2023 financial data (revenue of 0.7M€ and cash position as of June 30, 2023). It also includes operational updates, clinical trial progress, and management changes. This structure—a press release summarizing key financial figures for a specific interim period (Q2)—is characteristic of an Earnings Release (ER). It is not the full, comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of the period's results. Q2 2023
2023-07-27 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Earnings Release Classification · 100% confidence The document is titled "MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results." It explicitly details financial figures for Q2 2023 (cash position as of June 30, 2023, and revenues for Q2 2023) and provides a business update covering pipeline progress. This structure—a summary of recent financial performance for a specific interim period (Q2)—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it focuses on highlights and key metrics rather than full financial statements, although it contains some financial data. The presence of the CEO quote and pipeline updates further supports the ER classification, which typically precedes or accompanies a more detailed filing like an IR. Q2 2023
2023-07-27 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from MaaT Pharma dated July 26, 2023, announcing the publication of clinical data for their product MaaT013 in the journal *eClinicalMedicine* (part of The Lancet Discovery Science). The text details the positive results from Phase 2 and Compassionate Access Program (EAP) data regarding the treatment of acute graft-versus-host disease (aGvH). This type of announcement, which communicates key financial or operational results (in this case, clinical trial results) to the public and investors immediately upon release, aligns best with the definition of an Earnings Release (ER), even though the results are clinical rather than purely financial performance metrics. It is a primary announcement of significant operational/scientific progress. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a transcript (CT). Since it is the initial announcement of results, ER is the most appropriate fit over a general Regulatory Filing (RNS). The document length (9942 chars) is substantial enough to be the primary announcement itself, not just a brief notice of publication (RPA). FY 2023
2023-07-26 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is a press release titled "MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD". It details the publication of clinical data in a peer-reviewed journal (eClinicalMedicine) and discusses the results, safety profile, and ongoing Phase 3 trial (ARES). This structure—announcing the release of scientific or clinical data in an external publication—is characteristic of a press release intended to inform investors and the public about research progress. Since it is an announcement about the publication of results rather than the full regulatory filing (like 10-K or IR) or a general regulatory filing (RNS), and it doesn't fit the specific categories like ER, CT, or IP, the most appropriate classification is Report Publication Announcement (RPA), as it announces the publication of specific findings. Alternatively, given the content is scientific/clinical data dissemination, it could be argued as Investor Presentation (IP) if it were a slide deck, or Regulatory Filing (RNS) as a general announcement. However, RPA specifically covers announcements about the publication of reports/results.
2023-07-26 English
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated July 20, 2023, announcing that MaaT Pharma has joined the Microbiome Therapeutics Innovation Group (MTIG). It contains quotes from company executives and details about the organization. This type of announcement, which is not a formal regulatory filing like a 10-K, earnings release (ER), or a report itself, but rather a general corporate update or news item, fits best under the 'Regulatory Filings' (RNS) category as a general regulatory announcement or news release, as it does not specifically match any other defined category like Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV). Given the content is a general corporate announcement, RNS is the most appropriate fallback.
2023-07-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.